Biotech Networks

PNBN Trending News: Philadelphia life sciences sector cuts nearly 1,000 jobs in 2025 as investor caution grows https://lnkd.in/gB7SuAAZ Philadelphia’s life sciences sector is facing a wave of job cuts, with nearly 1,000 positions eliminated this year alone. Find out which companies have been affected and what’s driving this trend. Click here to view [...]

WOBN Trending News: Digital health company raises $28 million after move to Bellevue https://lnkd.in/gFSSBeXb The 10-year-old company aims expand its services and grow its sales and business development teams. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks Click here [...]

DCBN Trending News: Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma https://lnkd.in/gum4Edhv WILMINGTON, Del.–(BUSINESS WIRE)—- $INCY #ESMO25–Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced PDAC Click here to view original post Click Here to Publish/Feature Your [...]

NCBN Trending News: BioAgilytix Makes Multi-Million-Dollar Investments in LC/MS Capabilities https://lnkd.in/gKffNCb4 By harmonizing our platforms and processes, BioAgilytix says it can ensure that its customers can move assays efficiently between sites and trust that the same standards of excellence are maintained across regions. The post BioAgilytix [...]

PNBN Trending News: STAT+: Pharmalittle: We’re reading about ESMO cancer trial results, warnings from Moderna co-founder, and more https://lnkd.in/gExtJgwW Patients with an aggressive form of breast cancer will likely have new treatment options after AstraZeneca and Gilead presented successful trial results Click here to view original post Click Here to Publish/Feature Your Company or [...]

BCBN Trending News: Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 https://lnkd.in/gbmHXSKN NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presented as a [...]

LABN Trending News: Amgen, AZ’s Tezspire gains 2nd FDA nod, upping the ante in its battle with Dupixent https://lnkd.in/gupHUFYu The FDA has endorsed Amgen and AstraZeneca’s Tezspire as an add-on maintenance treatment for patients age 12 and older with chronic rhinosinusitis with nasal polyps. It is the second indication for Tezspire, which was originally [...]

SFBN Trending News: STAT+: At ESMO, AstraZeneca, Gilead square off in triple-negative breast cancer https://lnkd.in/gEPnV3iq BERLIN — Patients with a highly aggressive form of breast cancer will likely have new treatment options for the first time in years after AstraZeneca and Gilead Sciences both presented successful trial results here Sunday, [...]

I'm so pleased that David Shiffman is giving his talk "Shark conservation threats, solutions, and progress" at tomorrow's Biotech Networks virtual event https://lnkd.in/gMyZ3Tdt at 3 pm PT/6 pm ET David and I met in the early 2010's over our shared interest in science communication. David's compassion for shark conservation has led to the public's better understanding of Why Sharks Matter (his online identity) and an improvement in the health of the species. If you've heard me talk about scientist personal branding any time over the past 15 years (!) you'll likely remember that he's my favorite example. Join us to get an update on this important topic and to learn from David's example in how we all can better communicate our science to the public. After David's talk, stick around for the speed mentoring 4-6 pm US PT/7-9 pm US ET, and yes we STILL NEED MENTORS, PLEASE HELP US OUT!

SFBN Trending News: RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) https://lnkd.in/gqxG3vhd SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological [...]